Kyntra Bio (KYNB) Income from Continuing Operations (2014 - 2026)
Kyntra Bio (KYNB) posted Income from Continuing Operations of 15132000.0 for Q1 2026, down 515.62% sequentially from 2458000.0 in Q4 2025, and up 9.75% YoY from 13788212.61 in Q1 2025.
Kyntra Bio (KYNB) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Income from Continuing Operations for 13 years, with the latest figure at 15132000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 9.75% year-over-year to 15132000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44419000.0 (up 63.23% YoY) and the FY2025 annual result came in at 46052000.0, up 69.92% from the prior year.
- Income from Continuing Operations slipped to 15132000.0 in Q1 2026 per KYNB's latest filing, from 2458000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2458000.0 in Q4 2025 and troughed at 92947000.0 in Q4 2023.
- A 5-year average of 48969352.94 and a median of 49046000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 286.14% in 2022, then surged 90.68% in 2024.
- Over 5 years, Income from Continuing Operations stood at 66455000.0 in 2022, then sank by 39.86% to 92947000.0 in 2023, then soared by 90.68% to 8665000.0 in 2024, then jumped by 71.63% to 2458000.0 in 2025, then tumbled by 515.62% to 15132000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15132000.0, 2458000.0, and 13146000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 11.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.97 Mn |
| Mar 31, 2026 | -15.13 Mn |
| Dec 31, 2025 | -2.46 Mn |
| Sep 30, 2025 | -13.15 Mn |
| Jun 30, 2025 | -13.68 Mn |
| Mar 31, 2025 | -16.77 Mn |
| Dec 31, 2024 | -8.67 Mn |
| Sep 30, 2024 | -48.29 Mn |
| Jun 30, 2024 | -47.10 Mn |
| Mar 31, 2024 | -49.05 Mn |
| Dec 31, 2023 | -92.95 Mn |
| Sep 30, 2023 | -64.29 Mn |
| Jun 30, 2023 | -88.23 Mn |
| Mar 31, 2023 | -77.50 Mn |
| Dec 31, 2022 | -66.46 Mn |
| Sep 30, 2022 | -92.06 Mn |
| Jun 30, 2022 | -73.19 Mn |
| Mar 31, 2022 | -63.53 Mn |
| Dec 31, 2021 | -134.42 Mn |
| Sep 30, 2021 | 49.46 Mn |